The Intestinal Microbiota and Short-Chain Fatty Acids in Association with Advanced Metrics of Glycemia and Adiposity Among Young Adults with Type 1 Diabetes and Overweight or Obesity.
adiposity
body mass index
continuous glucose monitoring
dual-energy X-ray absorptiometry
glycemia
gut microbiota
hemoglobin A1c
short-chain fatty acids
type 1 diabetes
Journal
Current developments in nutrition
ISSN: 2475-2991
Titre abrégé: Curr Dev Nutr
Pays: United States
ID NLM: 101717957
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
24
03
2022
revised:
06
06
2022
accepted:
07
06
2022
entrez:
9
11
2022
pubmed:
10
11
2022
medline:
10
11
2022
Statut:
epublish
Résumé
Comanagement of glycemia and adiposity is the cornerstone of cardiometabolic risk reduction in type 1 diabetes (T1D), but targets are often not met. The intestinal microbiota and microbiota-derived short-chain fatty acids (SCFAs) influence glycemia and adiposity but have not been sufficiently investigated in longstanding T1D. We evaluated the hypothesis that an increased abundance of SCFA-producing gut microbes, fecal SCFAs, and intestinal microbial diversity were associated with improved glycemia but increased adiposity in young adults with longstanding T1D. Participants provided stool samples at ≤4 time points (NCT03651622: https://clinicaltrials.gov/ct2/show/NCT03651622). Sequencing of the 16S ribosomal RNA gene measured abundances of SCFA-producing intestinal microbes. GC-MS measured total and specific SCFAs (acetate, butyrate, propionate). DXA (body fat percentage and percentage lean mass) and anthropometrics (BMI) measured adiposity. Continuous glucose monitoring [percentage of time in range (70-180 mg/dL), above range (>180 mg/dL), and below range (54-69 mg/dL)] and glycated hemoglobin (i.e., HbA1c) assessed glycemia. Adjusted and Bonferroni-corrected generalized estimating equations modeled the associations of SCFA-producing gut microbes, fecal SCFAs, and intestinal microbial diversity with glycemia and adiposity. COVID-19 interrupted data collection, so models were repeated restricted to pre-COVID-19 visits. Data were available for ≤45 participants at 101 visits (including 40 participants at 54 visits pre-COVID-19). Abundance of Unexpectedly, fecal propionate was associated with detriment to glycemia, whereas most SCFA-producing intestinal microbes were associated with benefit to adiposity. Future studies should confirm these associations and determine their potential causal linkages in T1D.This study is registered at clinical.trials.gov (NCT03651622; https://clinicaltrials.gov/ct2/show/NCT03651622).
Sections du résumé
Background
UNASSIGNED
Comanagement of glycemia and adiposity is the cornerstone of cardiometabolic risk reduction in type 1 diabetes (T1D), but targets are often not met. The intestinal microbiota and microbiota-derived short-chain fatty acids (SCFAs) influence glycemia and adiposity but have not been sufficiently investigated in longstanding T1D.
Objectives
UNASSIGNED
We evaluated the hypothesis that an increased abundance of SCFA-producing gut microbes, fecal SCFAs, and intestinal microbial diversity were associated with improved glycemia but increased adiposity in young adults with longstanding T1D.
Methods
UNASSIGNED
Participants provided stool samples at ≤4 time points (NCT03651622: https://clinicaltrials.gov/ct2/show/NCT03651622). Sequencing of the 16S ribosomal RNA gene measured abundances of SCFA-producing intestinal microbes. GC-MS measured total and specific SCFAs (acetate, butyrate, propionate). DXA (body fat percentage and percentage lean mass) and anthropometrics (BMI) measured adiposity. Continuous glucose monitoring [percentage of time in range (70-180 mg/dL), above range (>180 mg/dL), and below range (54-69 mg/dL)] and glycated hemoglobin (i.e., HbA1c) assessed glycemia. Adjusted and Bonferroni-corrected generalized estimating equations modeled the associations of SCFA-producing gut microbes, fecal SCFAs, and intestinal microbial diversity with glycemia and adiposity. COVID-19 interrupted data collection, so models were repeated restricted to pre-COVID-19 visits.
Results
UNASSIGNED
Data were available for ≤45 participants at 101 visits (including 40 participants at 54 visits pre-COVID-19). Abundance of
Conclusions
UNASSIGNED
Unexpectedly, fecal propionate was associated with detriment to glycemia, whereas most SCFA-producing intestinal microbes were associated with benefit to adiposity. Future studies should confirm these associations and determine their potential causal linkages in T1D.This study is registered at clinical.trials.gov (NCT03651622; https://clinicaltrials.gov/ct2/show/NCT03651622).
Identifiants
pubmed: 36349343
doi: 10.1093/cdn/nzac107
pii: nzac107
pmc: PMC9620390
doi:
Banques de données
ClinicalTrials.gov
['NCT03651622']
Types de publication
Journal Article
Langues
eng
Pagination
nzac107Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition.
Références
ISME J. 2020 Jul;14(7):1809-1820
pubmed: 32313261
Diabetes Care. 2022 Feb 1;45(2):285-294
pubmed: 34995346
J Nutr. 2017 Jan;147(1):20-28
pubmed: 27903830
PLoS One. 2017 Dec 6;12(12):e0188475
pubmed: 29211757
Eur J Clin Nutr. 2012 Jul;66(7):789-94
pubmed: 22293570
Diabetes. 2015 Jul;64(7):2398-408
pubmed: 25695945
Nutr Clin Pract. 2012 Apr;27(2):201-14
pubmed: 22367888
Circulation. 2014 Sep 23;130(13):1110-30
pubmed: 25114208
Science. 2013 Jul 5;341(6141):1237439
pubmed: 23828941
Genome Biol. 2018 Feb 26;19(1):24
pubmed: 29478411
Science. 1973 Oct 12;182(4108):171-3
pubmed: 4581053
Int J Obes (Lond). 2009 Jul;33(7):758-67
pubmed: 19050675
Am J Clin Nutr. 2005 Mar;81(3):555-63
pubmed: 15755822
Nat Commun. 2013;4:1829
pubmed: 23652017
Diabetes. 2013 Apr;62(4):1238-44
pubmed: 23274889
Proc Nutr Soc. 2015 Aug;74(3):328-36
pubmed: 25497601
BMJ. 1995 Jan 21;310(6973):170
pubmed: 7833759
Nat Commun. 2014 Apr 29;5:3611
pubmed: 24781306
Pediatr Diabetes. 2010 Feb;11(1):4-11
pubmed: 19473302
Gastroenterology. 2012 Oct;143(4):913-6.e7
pubmed: 22728514
Gut. 2013 Aug;62(8):1112-21
pubmed: 23135760
Gene. 2014 Mar 1;537(1):85-92
pubmed: 24325907
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Diabetes. 2012 Feb;61(2):364-71
pubmed: 22190648
Nutrients. 2020 Jul 17;12(7):
pubmed: 32708978
Microbiome. 2017 Mar 3;5(1):27
pubmed: 28253908
Eur Eat Disord Rev. 2017 Sep;25(5):423-427
pubmed: 28586130
Diabetes Technol Ther. 2020 Jun;22(6):462-467
pubmed: 32421355
Science. 2016 Feb 19;351(6275):
pubmed: 26912898
Front Microbiol. 2016 May 19;7:713
pubmed: 27242734
Cell. 2014 Jan 16;156(1-2):84-96
pubmed: 24412651
Am J Clin Nutr. 2005 Sep;82(3):559-67
pubmed: 16155268
Nutrients. 2019 Oct 18;11(10):
pubmed: 31635264
J Nutr Biochem. 2019 Feb;64:228-236
pubmed: 30572270
PLoS Med. 2020 Mar 9;17(3):e1003051
pubmed: 32150549
Cell Metab. 2017 Oct 3;26(4):611-619.e6
pubmed: 28978426
Sci Rep. 2021 Mar 9;11(1):5532
pubmed: 33750881
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
Diabet Med. 2010 Apr;27(4):398-404
pubmed: 20536510
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):
pubmed: 33472859
Diabetes Care. 2015 Jun;38(6):971-8
pubmed: 25998289
World J Gastroenterol. 2007 May 28;13(20):2826-32
pubmed: 17569118
Gut. 2021 Jan;70(1):92-105
pubmed: 33106354
Cell. 2018 Sep 6;174(6):1406-1423.e16
pubmed: 30193113
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
PLoS One. 2011;6(10):e25792
pubmed: 22043294
Microbiome. 2018 Mar 21;6(1):55
pubmed: 29562936
J Am Diet Assoc. 1992 Jun;92(6):738-41
pubmed: 1607574
J Physiol. 2017 Jan 15;595(2):541-555
pubmed: 27510655
Nature. 2009 Jan 22;457(7228):480-4
pubmed: 19043404
Clin Trials. 2014 Apr 14;11(4):445-456
pubmed: 24733671
ISME J. 2019 Aug;13(8):1911-1919
pubmed: 30894688
Sci Rep. 2017 Aug 1;7(1):7046
pubmed: 28765642
Nat Commun. 2021 May 28;12(1):3105
pubmed: 34050144
Contemp Clin Trials Commun. 2018 Sep 21;12:68-75
pubmed: 30294698
Diabetes Care. 2018 Jun;41(6):e92-e94
pubmed: 29784704
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16767-72
pubmed: 18931303
Sci Rep. 2017 May 24;7(1):2360
pubmed: 28539646
BMC Med. 2013 Feb 21;11:46
pubmed: 23433344
Am J Epidemiol. 2003 Feb 15;157(4):364-75
pubmed: 12578807
Arch Biochem Biophys. 2019 Sep 15;672:108057
pubmed: 31356781
Gut. 1987 Oct;28(10):1221-7
pubmed: 3678950
PLoS One. 2012;7(4):e35240
pubmed: 22506074
NPJ Biofilms Microbiomes. 2020 Dec 2;6(1):60
pubmed: 33268781
BMC Gastroenterol. 2015 Aug 11;15:100
pubmed: 26261039
Science. 2009 Dec 18;326(5960):1694-7
pubmed: 19892944
Diabetologia. 2020 Mar;63(3):597-610
pubmed: 31915895
Cell. 2016 Jun 2;165(6):1332-1345
pubmed: 27259147
PLoS One. 2021 Nov 15;16(11):e0257154
pubmed: 34780485
J Pediatr. 2015 Sep;167(3):627-32.e1-4
pubmed: 26164381
Contemp Clin Trials. 2022 Jun;117:106765
pubmed: 35460915
Nat Rev Endocrinol. 2018 Aug;14(8):464-475
pubmed: 29946127
Diabetes Care. 2013 Aug;36(8):2346-50
pubmed: 23564922
Gut. 2020 Mar;69(3):502-512
pubmed: 31147381
Front Microbiol. 2019 Oct 23;10:2407
pubmed: 31708888
Am J Clin Nutr. 1979 Dec;32(12):2546-59
pubmed: 506977
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1247-1256
pubmed: 35080610
Environ Microbiol. 2010 Feb;12(2):304-14
pubmed: 19807780
Nutrients. 2018 Dec 27;11(1):
pubmed: 30591685
Clin Trials. 2004 Feb;1(1):9-20
pubmed: 16281458
Immunity. 2014 Jan 16;40(1):128-39
pubmed: 24412617
BMC Genomics. 2014 Jun 21;15:511
pubmed: 24952588
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
Horm Metab Res. 2017 Nov;49(11):886-891
pubmed: 28962046
Nat Rev Endocrinol. 2015 Oct;11(10):577-91
pubmed: 26260141
Stat Med. 2005 May 30;24(10):1455-81
pubmed: 15586395